Kürşad ZENGİN, Hüseyin EDE, Serhat TANIK, Sebahattin ALBAYRAK, Savaş SARIKAYA, Aliriza ERBAY, Muhammet Abdurrahim İMAMOĞLU, Mesut GÜRDAL

Cardiac factors affecting the success of vardenafil in erectile dysfunction

Background/aim: To evaluate the predictability of vardenafil success in patients with erectile dysfunction (ED) by using cardiological tests. Materials and methods: Patients diagnosed with ED who did not benefit from lifestyle changes (n = 68) were evaluated with an abridged 5-item version of the International Index of Erectile Function (IIEF-5). The pretreatment and posttreatment IIEF-5 scores were compared with pretreatment data obtained from cardiological examinations. Results: When pretreatment scores were compared with test parameters, mitral flow E/A ratio and tissue Doppler imaging (TDI) E?/A?, exercise test duration, exercise capacity in MET, and percentage of maximum heart rate were found to be statistically significant. Furthermore, there was a significant negative correlation between mitral flow E/A ratio, TDI E?/A?, exercise test duration, exercise capacity in MET, and the difference in post- and pretreatment IIEF-5 scores. Conclusion: As a diastolic function indicator, TDI E?/A? positively correlates with pretreatment IIEF-5 scores and negatively correlates with the beneficial effect of vardenafil treatment. As a result, the cardiological status of the patient correlates with individual IIEF-5 scores, and it seems to be useful in predicting vardenafil success.

Anahtar Kelimeler:

Erectile dysfunction, phosphodiesterase type 5 inhibitor, diastolic dysfunction

Cardiac factors affecting the success of vardenafil in erectile dysfunction

Keywords:

Erectile dysfunction, phosphodiesterase type 5 inhibitor, diastolic dysfunction,

PDF

___

Souverein PC, Egberts AC, Meuleman EJ, Urquhart J, Leufkens HG. Incidence and determinants of sildenafil (dis) continuation: the Dutch cohort of sildenafil users. Int J Impot Res 2002; 14: 259–265.
Murad Basar M, Atan A, Tekdogan ÜY, Batislam E. A classification based on peak systolic velocity and end diastolic velocity predicts sildenafil citrate success. Scand J Urol Nephrol 2003; 37: 502–506.
El-Sakka AI, Morsy AM, Fagih BI. Severity of erectile dysfunction could predict left ventricular diastolic dysfunction in patients without overt cardiac complaint. J Sex Med 2011; 8: 2590–2597.
Jackson G, Nehra A, Miner M, Billups KL, Burnett AL, Buvat J, Carson CC, Cunningham G, Goldstein I, Guay AT et al. The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. Int J Clin Pract 2013; 67: 1163–1172.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.
Canat L, Cicek G, Atis G, Gurbuz C, Caskurlu T. Is there a relationship between severity of coronary artery disease and severity of erectile dysfunction? Int Braz J Urol 2013; 39: 465– 473.
Solak Y, Akilli H, Kayrak M, Aribas A, Gaipov A, Turk S, Perez-Pozo SE, Covic A, McFann K, Johnson RJ et al. Uric acid level and erectile dysfunction in patients with coronary artery disease. J Sex Med 2014; 11: 165–172.
Kligfield P, Lauer MS. Exercise electrocardiogram testing: beyond the ST segment. Circulation 2006; 114: 2070–2082.
Dogru MT, Basar MM, Haciislamoglu A. The difference of heart rate recovery between males with and without erectile dysfunction. Ann Noninvasive Electrocardiol 2010; 15: 223– 229.
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27–III32.
Javaroni V, Queiroz-Miguez M, Abreu-Casanova M, Oigman W, Neves MF. Brachial flow-mediated dilation correlates with vardenafil response in hypertensive men with vasculogenic erectile dysfunction. Urology 2011; 78: 368–374.